| Literature DB >> 31481899 |
Hoyoon Lee1, Wonwhi Na1, Sang Bae Lee2, Chul Woo Ahn2, Jun Sung Moon3, Kyu Chang Won3, Sehyun Shin1.
Abstract
Many studies have demonstrated that an alteration in hemorheological properties is closely correlated with diabetic microcirculatory diseases. However, most of these studies have been limited to animal studies or used a small number of clinical samples, due to a lack of effective point-of-care (POC) devices to measure such properties within clinical environments. Owing to recent developments in microfluidic technology, several hemorheological POC devices have been designed that allow for the possibility of conducting extensive clinical studies using hemorheological measurements. Here, we reviewed recent clinical studies of diabetic kidney disease (DKD) associated with hemorheological parameters. We found that RBC deformability alone did not show a significant difference according to the degree of DKD, whereas critical shear stress (CSS) was found to be closely related to the ratio of albumin to creatinine and glomerular filtration rate. We also reviewed studies that alteration of hemorheological properties are associated with the development of DKD, which showed that CSS could be considered as a potential index to diagnose other diabetic complications as well as DKD.Entities:
Keywords: chronic kidney disease; critical shear stress; deformability; diabetic nephropathy; diagnosis
Year: 2019 PMID: 31481899 PMCID: PMC6710411 DOI: 10.3389/fphys.2019.01062
Source DB: PubMed Journal: Front Physiol ISSN: 1664-042X Impact factor: 4.566
FIGURE 1Schematic of hemorheological alteration in diabetes mellitus.
FIGURE 2Schematic of microfluidic ektacytometry to measure red blood cell deformability (reproduced with permission from Shin et al., 2007a).
Determinants of RBC Hemorheology and measurement techniques.
| Deformability | ||
| Aggregation | ||
| Critical shear stress, CSS (or critical shear rate, CSR) |
FIGURE 3Schematic of microfluidic aggregometry to measure critical shear stress.
Clinical association of hemorheological properties with diabetic nephropathy.
| Diabetic mellitus | [ |
| Diabetic Nephropathy | |
Hemorheological parameters of a study population according to chronic kidney disease (CKD) stages.
| Fibrinogen (mg/dL) | 270.63 (56.57) | 307.19a (83.35) | 315.76b (86.86) | 311.27c (67.82) | 357.80d (77.52) | <0.001 |
| ESR (mm/h) | 14.36 (12.52) | 25.29(22.21)a | 27.19b(22.99) | 31.67c(20.55) | 51.80d,e,f,g(23.20) | <0.001 |
| EI | 0.3218 (0.0180) | 0.3227 (0.0122) | 0.3144 (0.0253) | 0.3159 (0.0160) | 0.3139 (0.0136) | 0.048 |
| Critical shear stress (Pa) | 262.79 (131.24) | 318.96 (151.73) | 318.10 (194.15) | 298.90 (158.84) | 329.70 (83.81) | 0.028 |
| Fibrinogen/CSS | 789.07 (460.60) | 999.56 (526.91) | 1037.17 (736.81) | 953.36 (535.05) | 1055.12 (284.49) | 0.004 |
| Fibrinogen/EI | 807.13 (248.20) | 953.92a (268.55) | 957.31 (314.17) | 989.52c (230.00) | 1144.98d (270.62) | <0.001 |
| ESR/EI | 45.16 (41.15) | 78.12a (68.39) | 84.27b (66.36) | 100.44 | 165.07d,e,f,g(73.59) | <0.001 |
| (Fibrinogen × ESR)/EI | 13434 (15805) | 26518a (30729) | 30997b (34407)b | 33872c (27345) | 61503d,e,f,g (34934) | <0.001 |
Baseline characteristics of patients based on the estimated glomerular filtration rate (eGFR) (n = 421).
| Sex(M:F) | I.5:1 | 1.30:1 | 0.588 |
| Age (Yrs) | 56.36 ± 11.11 | 66.03 ± 9.85 | < 0.001 |
| BMI (Kg/m2) | 24.99 ± 7.47 | 23.84 ± 3.43 | 0.070 |
| Diabetes duration (Yrs) | 7.16 ± 7.22 | 13.69 ± 9.37 | < 0.001 |
| HTN(n(%)) | 180 (53.4) | 62 (82.7) | < 0.001 |
| FPG(mg/dL) | 165.64 ± 52.34 | 176.35 ± 67.27 | 0.299 |
| HbAlc(%) | 8.19 ± 2.02 | 8.77 ± 2.67 | 0.098 |
| HOMA-IR | 4.52 ± 3.79 | 4.51 ± 2.50 | 0.981 |
| HOMA-B | 48.19 ± 37.72 | 46.89 ± 46.92 | 0.860 |
| Hb (g/dL) | 14.37 ± 1.54 | 12.51 ± 1.86 | < 0.001 |
| T-Cho (mg/dL) | 181.27 ± 44.23 | 173.26 ± 55.29 | 0.241 |
| HDL-Cho (mg/dL) | 51.76 ± 13.91 | 47.10 ± 15.54 | 0.020 |
| LDL-Cho (mg/dL) | 96.12 ± 38.66 | 90.04 ± 46.38 | 0.299 |
| TG(mg/dL) | 169.61 ± 110.06 | 184.16 ± 114.05 | 0.322 |
| ESR(mm/H) | 20.01 ± 20.83 | 40.67 ± 28.80 | < 0.001 |
| hsCRP (mg/dl.) | 0.28 ± 0.71 | 0.57 ± 1.30 | 0.099 |
| Fibrinogen (mg/dL) | 311.21 ± 54.78 | 338.44 ± 58.57 | 0.018 |
| CS5(mPa) | 317.43 ± 125.11 | 385.22 ± 182.89 | < 0.001 |
| EI@3Pa (%) | 30.60 ± 1.91 | 30.42 ± 20.54 | 0.481 |
| Fibrinogen/EI@3Pa (mg/dI.%) | 1033.28 ± 197.76 | 1141.44 ± 268.71 | 0.045 |
| DR(%) | 32.0 | 46.5 | 0.019 |
| DPN(%) | 15.4 | 29.3 | 0.004 |
| CAD(%) | 8.4 | 23.7 | < 0.001 |